327 related articles for article (PubMed ID: 37458856)
1. Ferrozoles: Ferrocenyl derivatives of letrozole with dual effects as potent aromatase inhibitors and cytostatic agents.
Diaz de Greñu B; Fernández-Aroca DM; Organero JA; Durá G; Jalón FA; Sánchez-Prieto R; Ruiz-Hidalgo MJ; Rodríguez AM; Santos L; Albasanz JL; Manzano BR
J Biol Inorg Chem; 2023 Sep; 28(6):531-547. PubMed ID: 37458856
[TBL] [Abstract][Full Text] [Related]
2. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
[TBL] [Abstract][Full Text] [Related]
3. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A
Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
5. Design and Pharmacophore Study of Triazole Analogues as Aromatase Inhibitors.
Banjare L
Anticancer Agents Med Chem; 2024; 24(4):288-303. PubMed ID: 37921212
[TBL] [Abstract][Full Text] [Related]
6. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
Abrhale T; Brodie A; Sabnis G; Macedo L; Tian C; Yue B; Serrero G
BMC Cancer; 2011 Jun; 11():231. PubMed ID: 21658239
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities.
A A Fadaly W; A M M Elshaier Y; T M Nemr M; R A Abdellatif K
Bioorg Chem; 2023 May; 134():106428. PubMed ID: 36893546
[TBL] [Abstract][Full Text] [Related]
8. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, Docking Studies and Biological Activity of New Benzimidazole- Triazolothiadiazine Derivatives as Aromatase Inhibitor.
Acar Çevik U; Kaya Çavuşoğlu B; Sağlık BN; Osmaniye D; Levent S; Ilgın S; Özkay Y; Kaplancıklı ZA
Molecules; 2020 Apr; 25(7):. PubMed ID: 32252458
[TBL] [Abstract][Full Text] [Related]
10. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
Ju YH; Doerge DR; Woodling KA; Hartman JA; Kwak J; Helferich WG
Carcinogenesis; 2008 Nov; 29(11):2162-8. PubMed ID: 18632754
[TBL] [Abstract][Full Text] [Related]
11. Interaction of letrozole and its degradation products with aromatase: chemometric assessment of kinetics and structure-based binding validation.
De Luca M; Occhiuzzi MA; Rizzuti B; Ioele G; Ragno G; Garofalo A; Grande F
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1600-1609. PubMed ID: 35635194
[TBL] [Abstract][Full Text] [Related]
12. [Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model].
Chen HY; Liu ZH
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):423-8. PubMed ID: 24119901
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Hirakawa H; Yokoyama Y; Yoshida H; Mizunuma H
J Ovarian Res; 2014 Jan; 7():4. PubMed ID: 24410765
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction.
Schech AJ; Nemieboka BE; Brodie AH
J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):195-202. PubMed ID: 22659283
[TBL] [Abstract][Full Text] [Related]
15. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
Masri S; Liu Z; Phung S; Wang E; Yuan YC; Chen S
Breast Cancer Res Treat; 2010 Nov; 124(1):89-99. PubMed ID: 20054641
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Biological Evaluation of New Azole Derivatives as Potent Aromatase Inhibitors with Potential Effects against Breast Cancer.
Kalalinia F; Jouya M; Komachali AK; Aboutourabzadeh SM; Karimi G; Behravan J; Abnous K; Etemad L; Kamali H; Hadizadeh F
Anticancer Agents Med Chem; 2018; 18(7):1016-1024. PubMed ID: 29336269
[TBL] [Abstract][Full Text] [Related]
17. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
[TBL] [Abstract][Full Text] [Related]
18. Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates.
Wood PM; Woo LW; Thomas MP; Mahon MF; Purohit A; Potter BV
ChemMedChem; 2011 Aug; 6(8):1423-38. PubMed ID: 21608133
[TBL] [Abstract][Full Text] [Related]
19. Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activity.
Wood PM; Woo LW; Labrosse JR; Trusselle MN; Abbate S; Longhi G; Castiglioni E; Lebon F; Purohit A; Reed MJ; Potter BV
J Med Chem; 2008 Jul; 51(14):4226-38. PubMed ID: 18590272
[TBL] [Abstract][Full Text] [Related]
20. Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
Banerjee S; A'Hern R; Detre S; Littlewood-Evans AJ; Evans DB; Dowsett M; Martin LA
Clin Cancer Res; 2010 Aug; 16(16):4178-87. PubMed ID: 20682704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
